The effect of deprenyl and levodopa on the progression of Parkinson's disease
Identifieur interne : 002275 ( Main/Exploration ); précédent : 002274; suivant : 002276The effect of deprenyl and levodopa on the progression of Parkinson's disease
Auteurs : Olanow [États-Unis] ; R. A. Hauser [États-Unis] ; L. Gauguster [États-Unis] ; T. Malapira [États-Unis] ; W. Koller [États-Unis] ; J. Hubble [États-Unis] ; K. Bushenbark [États-Unis] ; D. Lilienfeld [États-Unis] ; J. Esterlitz [États-Unis]Source :
- Annals of Neurology [ 0364-5134 ] ; 1995-11.
Abstract
We have performed a 14‐month, prospective, randomized, double‐blind, placebo‐controlled study to evaluate the effect of deprenyl and levodopa/carbidopa (Sinemet) on the progression of signs and symptoms in patients with mild Parkinson's disease (PD). One hundred one untreated PD patients were randomly assigned to one of the following four treatment groups: Group I, deprenyl + Sinemet; Group II, placebo‐deprenyl + Sinemet; Group III, deprenyl + bromocriptine; and Group IV, placebo‐deprenyl + bromocriptine. The final visit was performed at 14 months, i.e., 2 months after withdrawal of deprenyl or its placebo and 7 days after withdrawal of Sinemet or bromocriptine. Deterioration in Unified Parkinson's Disease Rating Score (UPDRS) between untreated baseline and final visits was used as an index of disease progression. Placebo‐treated patients deteriorated by 5.8 ± 1.4 points, while deprenyl‐treated patients deteriorated by 0.4 ± 1.3 points (p < 0.001). This effect was sufficiently powerful that a significant deprenyl effect could be detected in the subgroup of 41 patients randomized to Sinemet (p < 0.01) as well as in the 23 patients who completed a 14‐day washout of Sinemet or bromocriptine (p < 0.05). No difference in the extent of deterioration was detected in patients randomized to Sinemet versus bromocriptine. This study demonstrates that deprenyl attenuates deterioration in UPDRS score in patients with early PD. These findings are not readily explained by the drug's symptomatic effects and are consistent with the hypothesis that deprenyl has a neuroprotective effect.
Url:
DOI: 10.1002/ana.410380512
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The effect of deprenyl and levodopa on the progression of Parkinson's disease</title><author><name sortKey="Olanow" sort="Olanow" uniqKey="Olanow" last="Olanow">Olanow</name></author><author><name sortKey="Hauser, R A" sort="Hauser, R A" uniqKey="Hauser R" first="R. A." last="Hauser">R. A. Hauser</name></author><author><name sortKey="Gauguster, L" sort="Gauguster, L" uniqKey="Gauguster L" first="L." last="Gauguster">L. Gauguster</name></author><author><name sortKey="Malapira, T" sort="Malapira, T" uniqKey="Malapira T" first="T." last="Malapira">T. Malapira</name></author><author><name sortKey="Koller, W" sort="Koller, W" uniqKey="Koller W" first="W." last="Koller">W. Koller</name></author><author><name sortKey="Hubble, J" sort="Hubble, J" uniqKey="Hubble J" first="J." last="Hubble">J. Hubble</name></author><author><name sortKey="Bushenbark, K" sort="Bushenbark, K" uniqKey="Bushenbark K" first="K." last="Bushenbark">K. Bushenbark</name></author><author><name sortKey="Lilienfeld, D" sort="Lilienfeld, D" uniqKey="Lilienfeld D" first="D." last="Lilienfeld">D. Lilienfeld</name></author><author><name sortKey="Esterlitz, J" sort="Esterlitz, J" uniqKey="Esterlitz J" first="J." last="Esterlitz">J. Esterlitz</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D79D447E49BC0522CF8AB89FFB004A307AE733F9</idno><date when="1995" year="1995">1995</date><idno type="doi">10.1002/ana.410380512</idno><idno type="url">https://api.istex.fr/document/D79D447E49BC0522CF8AB89FFB004A307AE733F9/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000A23</idno><idno type="wicri:Area/Main/Curation">000893</idno><idno type="wicri:Area/Main/Exploration">002275</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The effect of deprenyl and levodopa on the progression of Parkinson's disease</title><author><name sortKey="Olanow" sort="Olanow" uniqKey="Olanow" last="Olanow">Olanow</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Department of Neurology, Mount Sinai Medical Center, New York</wicri:cityArea></affiliation></author><author><name sortKey="Hauser, R A" sort="Hauser, R A" uniqKey="Hauser R" first="R. A." last="Hauser">R. A. Hauser</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Floride</region></placeName><wicri:cityArea>Department of Neurology, University of South Florida, Tampa</wicri:cityArea></affiliation></author><author><name sortKey="Gauguster, L" sort="Gauguster, L" uniqKey="Gauguster L" first="L." last="Gauguster">L. Gauguster</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Floride</region></placeName><wicri:cityArea>Department of Neurology, University of South Florida, Tampa</wicri:cityArea></affiliation></author><author><name sortKey="Malapira, T" sort="Malapira, T" uniqKey="Malapira T" first="T." last="Malapira">T. Malapira</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Floride</region></placeName><wicri:cityArea>Department of Neurology, University of South Florida, Tampa</wicri:cityArea></affiliation></author><author><name sortKey="Koller, W" sort="Koller, W" uniqKey="Koller W" first="W." last="Koller">W. Koller</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Kansas</region></placeName><wicri:cityArea>Department of Neurology, University of Kansas Medical Center, Kansas City</wicri:cityArea></affiliation></author><author><name sortKey="Hubble, J" sort="Hubble, J" uniqKey="Hubble J" first="J." last="Hubble">J. Hubble</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Kansas</region></placeName><wicri:cityArea>Department of Neurology, University of Kansas Medical Center, Kansas City</wicri:cityArea></affiliation></author><author><name sortKey="Bushenbark, K" sort="Bushenbark, K" uniqKey="Bushenbark K" first="K." last="Bushenbark">K. Bushenbark</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Kansas</region></placeName><wicri:cityArea>Department of Neurology, University of Kansas Medical Center, Kansas City</wicri:cityArea></affiliation></author><author><name sortKey="Lilienfeld, D" sort="Lilienfeld, D" uniqKey="Lilienfeld D" first="D." last="Lilienfeld">D. Lilienfeld</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>EMMES Corporation, Potomac</wicri:cityArea></affiliation></author><author><name sortKey="Esterlitz, J" sort="Esterlitz, J" uniqKey="Esterlitz J" first="J." last="Esterlitz">J. Esterlitz</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>EMMES Corporation, Potomac</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1995-11">1995-11</date><biblScope unit="volume">38</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="771">771</biblScope><biblScope unit="page" to="777">777</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">D79D447E49BC0522CF8AB89FFB004A307AE733F9</idno><idno type="DOI">10.1002/ana.410380512</idno><idno type="ArticleID">ANA410380512</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We have performed a 14‐month, prospective, randomized, double‐blind, placebo‐controlled study to evaluate the effect of deprenyl and levodopa/carbidopa (Sinemet) on the progression of signs and symptoms in patients with mild Parkinson's disease (PD). One hundred one untreated PD patients were randomly assigned to one of the following four treatment groups: Group I, deprenyl + Sinemet; Group II, placebo‐deprenyl + Sinemet; Group III, deprenyl + bromocriptine; and Group IV, placebo‐deprenyl + bromocriptine. The final visit was performed at 14 months, i.e., 2 months after withdrawal of deprenyl or its placebo and 7 days after withdrawal of Sinemet or bromocriptine. Deterioration in Unified Parkinson's Disease Rating Score (UPDRS) between untreated baseline and final visits was used as an index of disease progression. Placebo‐treated patients deteriorated by 5.8 ± 1.4 points, while deprenyl‐treated patients deteriorated by 0.4 ± 1.3 points (p < 0.001). This effect was sufficiently powerful that a significant deprenyl effect could be detected in the subgroup of 41 patients randomized to Sinemet (p < 0.01) as well as in the 23 patients who completed a 14‐day washout of Sinemet or bromocriptine (p < 0.05). No difference in the extent of deterioration was detected in patients randomized to Sinemet versus bromocriptine. This study demonstrates that deprenyl attenuates deterioration in UPDRS score in patients with early PD. These findings are not readily explained by the drug's symptomatic effects and are consistent with the hypothesis that deprenyl has a neuroprotective effect.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Floride</li><li>Kansas</li><li>Maryland</li><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Olanow" sort="Olanow" uniqKey="Olanow" last="Olanow">Olanow</name></region><name sortKey="Bushenbark, K" sort="Bushenbark, K" uniqKey="Bushenbark K" first="K." last="Bushenbark">K. Bushenbark</name><name sortKey="Esterlitz, J" sort="Esterlitz, J" uniqKey="Esterlitz J" first="J." last="Esterlitz">J. Esterlitz</name><name sortKey="Gauguster, L" sort="Gauguster, L" uniqKey="Gauguster L" first="L." last="Gauguster">L. Gauguster</name><name sortKey="Hauser, R A" sort="Hauser, R A" uniqKey="Hauser R" first="R. A." last="Hauser">R. A. Hauser</name><name sortKey="Hubble, J" sort="Hubble, J" uniqKey="Hubble J" first="J." last="Hubble">J. Hubble</name><name sortKey="Koller, W" sort="Koller, W" uniqKey="Koller W" first="W." last="Koller">W. Koller</name><name sortKey="Lilienfeld, D" sort="Lilienfeld, D" uniqKey="Lilienfeld D" first="D." last="Lilienfeld">D. Lilienfeld</name><name sortKey="Malapira, T" sort="Malapira, T" uniqKey="Malapira T" first="T." last="Malapira">T. Malapira</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002275 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002275 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:D79D447E49BC0522CF8AB89FFB004A307AE733F9
|texte= The effect of deprenyl and levodopa on the progression of Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |